$LMNL Short the crap. Tight stop-lossLook left NASDAQ:LMNL on daily.
All the pumps followed by the dumps next day.
Close below open - 78%
Avg. fade - 17%
Avg. low - 28%
We aim 23% on the backside here.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
About Liminal BioSciences Inc.
Sector
Industry
CEO
Bruce Philip Pritchard
Website
Headquarters
Laval
Founded
1994
Liminal BioSciences, Inc. operates as a clinical stage biopharmaceutical company. The firm focuses on developing distinctive novel small molecule therapeutics for inflammatory, fibrotic, and metabolic diseases using drug discovery platform and a data driven approach. The firm has business operations in Canada and the United Kingdom. Its small molecule product candidate, fezagepras, has completed a Phase 1 multi-ascending dose clinical trial and anticipate conducting a comparative Phase 1a single ascending dose clinical trial to provide comparative data to support development plan. The company was founded on October 14, 1994 and is headquartered in Laval, Canada.
Tangent school: LMNL BuyLimit@4.99 Break through the trend lineTangent school: LMNL BuyLimit@4.99 Break through the trend line
LMNLI called Liminal BioSciences Inc (NASDAQ:LMNL) recently at $4.40 as a potential big runner due to the PDUFA catalyst. On Friday, just a few minutes before the close, the stock was halted and the U.S. Food & Drug Administration (FDA) announced the approval of Ryplazim® (plasminogen, human-tvmh) ("Ry
LMNL up and awaynew catalyst on 4 th of june, FDA approval on ryplazim. this stock has been very weak for a while now. big movement imminent on monday
LMNL to double or quadruple within 6-12 months?DISCLAIMER: I'm not a certified or licensed financial advisor, securities trader, or securities broker; and, this is not intended as financial or securities advice.
Hopefully, my observations are improving. Using two separate 2 over 2 layouts for my version of multiple time frame analysis . Trackin
mid term +6,000%Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on discovery, development, and commercialization of novel small molecule drug candidates for the treatment of patients suffering from respiratory fibrotic diseases and other fibrotic or inflammatory diseases that have high
Liminal BioSciences, a risky play85% below the July peak of last year and 99% below its all-time high.
Orbiting a major support level around $4.
A capital injection began in mid-November that is still not properly reflected in price.
Stochastic at the oversold point and RSI close to touching it.
It could give the surprise of gi
LMNL subliminal chart messagesLMNL is a biopharma company of no incredible significance, but I thought the chart patterns were worth sharing. First and foremost, look at the runup in volume! Trapped beneath downtrend resistance, I'd venture to guess it's undergoing heavy accumulation. If it breaks through downtrend resistance,
See all ideas
Frequently Asked Questions
Delisting occurs when a security is removed from a stock exchange, either voluntarily or involuntarily. It happens for various reasons: some companies do it as they cease all operations, others opt for it as the result of bankruptcy. Among other reasons there are merging with another company, failing to meet listing requirements, or the transition to private ownership.
A stock's fate depends on the way the company delisted. If it delisted voluntarily, its shareholders typically receive cash as a buyout or corresponding shares in the acquiring company. However, when a company is forced to delist, shareholders have to either find a buyer on the exchange, or keep holding shares of an unlisted company.
LMNL reached its all-time high on Apr 28, 2016 with the price of 27,739.00 USD, and its all-time low was 3.10 USD and was reached on Jan 3, 2023. View more price dynamics on LMNL chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.